Skip to main content
Category

Amphista Therapeutics

Amphista Therapeutics appoints Antony Mattessich as Chief Executive Officer

By Amphista Therapeutics, Press Release, Private Companies
Press Release.

 

Amphista Therapeutics appoints Antony Mattessich as Chief Executive Officer

  • The appointment will accelerate the Company’s next phase of growth, advancing its next generation Targeted Glue™ protein degraders into the clinic and building a robust pipeline
  • Appointment follows achievement of three key milestones for Amphista in 2024 which demonstrated: in vivo efficacy, ability to target and degrade proteins in the CNS and novel mechanism of action for the degradation of proteins

Cambridge, UK, 3 September 2024 – Amphista Therapeutics (“the Company” or “Amphista”), a leader in next generation targeted protein degradation (TPD) approaches, today announces the appointment of Antony Mattessich as its Chief Executive Officer (CEO) and member of the Board of Directors. The appointment of Antony Mattessich as CEO will steer Amphista through its next phase of growth.

Antony is an experienced CEO bringing an impressive track record progressing programs from discovery, through clinical development and commercial success. He has strong capital markets experience having raised over $750 million for companies throughout his career. Antony has held several senior executive positions where he was instrumental in developing medicines that translate innovative science into meaningful clinical outcomes for patients, with extensive experience in CNS, haemato-oncology, immunology, and metabolics. For the last seven years, Antony was President and CEO of Nasdaq-listed Ocular Therapeutix (OCUL), where he launched the company’s lead asset and brought its potential blockbuster in Wet Age-Related Macular Degeneration (wet-AMD) from pre-clinical development into active enrolment in Phase 3.

Antony Mattessich, Chief Executive Officer of Amphista said: “2024 has been a pivotal year for Amphista and I am thrilled to join a company that has such differentiated technology in the TPD space at a really exciting time in its development. Having worked extensively in bringing therapies to patients, I am excited to focus on building Amphista’s portfolio of first-and best-in-class degraders into medicines that transform the lives of patients. The promising pre-clinical data that continues to mount at Amphista is testament to the strength of its scientific team. I am looking forward to working alongside the exceptional leadership team as well as its talented board of directors.

Joshua Brumm, Chairman of Amphista’s Board of Directors said: “Antony’s extensive drug development and capital markets expertise are a perfect fit for Amphista as we plan to advance our lead assets into clinical development following the compelling new in vivo efficacy and CNS activity data announced this year. We are delighted to have someone with Antony’s leadership and track record joining at such a transformational time for Amphista.

In January 2024, the Company announced the achievement of two new data sets with its next generation bifunctional non-cereblon / non-VHL-based protein degraders. This was followed in May 2024 by the unveiling of a new mechanism of action for the degradation of BRD9, an emerging target in oncology, that is differentiated from cereblon- or VHL-based PROTACs.

About Amphista Therapeutics

Amphista Therapeutics is focused on transforming the lives of patients with severe diseases, including cancer and neurodegenerative disease, through the advancement of next generation targeted protein degradation (TPD) medicines. Amphista is applying its proprietary warhead chemistry and mechanistic know-how to generate bifunctional Targeted Glues® with a differentiated mechanism and leading physicochemical properties. Its portfolio offers the potential for first- and/or best-in-class assets and expanding the offering of TPD medicines beyond CRBN and VHL-based agents. Founded by Advent Life Sciences, Amphista is a spin-out of TPD expert Professor Alessio Ciulli’s laboratories at the University of Dundee. Amphista is funded by leading life science investors including Advent Life Sciences, Forbion, Gilde Healthcare, Novartis Venture Fund, SV’s Dementia Discovery Fund as well as Eli Lilly & Company, and has strategic collaborations with Bristol Myers Squibb and Merck KGaA. For more information, please visit: www.amphista.com

 

Amphista, Targeted Glue, Targeted Glues and the Amphista logo are all trademarks or registered trademarks of Amphista Therapeutics Limited.

For more information please contact:

Amphista Therapeutics
John Goodall
Info@amphista.com

ICR Consilium
Amber Fennell, Namrata Taak Emily Johnson
Email: Amphista@consilium-comms.com
Tel: +44 (0)20 3709 5813

Amphista Therapeutics unveils new differentiated mechanism of action for BRD9 degradation at 2024 Protein Degradation in Focus Symposium

By Amphista Therapeutics, Press Release, Private Companies
Press Release.

 

Amphista Therapeutics unveils new differentiated mechanism of action for BRD9 degradation at 2024 Protein Degradation in Focus Symposium

  • First presentation of a novel mechanism of action for the degradation of BRD9 – completely differentiated from cereblon- or VHL-based PROTACs
  • Amphista’s bifunctional BRD9 degraders selectively induce BRD9 to DCAF16 proximity and serve as molecular glues, leading to strong and rapid degradation of BRD9
  • Discovery further underscores Amphista’s proprietary chemistry and high-quality science which is being applied to the discovery and development of additional targeted glues beyond BRD9

Cambridge, UK, May 23, 2024 – Amphista Therapeutics (“Amphista”), a leader in next generation targeted protein degradation (TPD) approaches, today announces the unveiling of a new mechanism of action for the degradation of BRD9, an emerging target in oncology, that is differentiated from cereblon- or VHL-based PROTACs, during an oral presentation at the 2024 Protein Degradation in Focus Symposium held in Dundee, UK.

This significant news for the TPD field builds upon an earlier announcement by Amphista of two compelling data sets demonstrating in vivo efficacy and central nervous system (CNS) activity of its mechanistically differentiated protein degraders. At today’s presentation titled “Degradation of BRD9 by a novel targeted glue”, Dr Andrea Testa, Scientific Co-Founder and Senior Director, Discovery Chemistry showed data from proteomic and genetic validation studies which demonstrate that Amphista’s bifunctional degraders induced degradation of BRD9 by target-assisted E3 ligase recruitment. This novel mechanism selectively induces the proximity of BRD9 to DCAF16 and serves as a molecular glue. DCAF16 is a cullin-RING E3 ligase which can facilitate degradation of proteins of interest via ternary complex formation. Induction of this complex leads to deep and rapid degradation of BRD9 in vivo.

Louise Modis, Chief Scientific Officer of Amphista Therapeutics, said: “The discovery of a novel mechanism for BRD9 degradation, differentiated from cereblon- or VHL-based PROTACs, is a testament to Amphista’s proprietary chemistry and know-how. Our ability to translate this novel approach into high-quality, drug-like compounds with oral bioavailability and activity in vivo is truly exciting. As we continue to spearhead our efforts to advance new TPD approaches, our goal remains clear – to expand the offering of TPD medicines beyond CRBN and VHL-based agents and bring effective treatments to patients in areas of high unmet need.”

In the results presented, Amphista’s sub-nanomolar BRD9 degraders showed activity in both solid and liquid cancer cell lines and demonstrated a high degree of selectivity over 8,000 proteins quantified by proteomics, including the closely related proteins BRD7 and BRD4. Notably, these compounds induced BRD9 degradation in a mouse xenograft model illustrating Amphista’s BRD9 degraders are orally bioavailable and active in vivo. This is the first-time in vivo degradation of BRD9 has been demonstrated via DCAF16, underscoring the potential therapeutic application of Amphista’s bifunctional degraders.

Building on this knowledge, Amphista is applying its proprietary scientific know-how and expertise to the development of targeted glues which induce degradation of different targets, expanding the opportunity beyond BRD9. Future announcements will provide details of additional pipeline targets as part of Amphista’s ambitions to develop a first- and/or best-in-class portfolio of degraders with leading physicochemical properties.

About Amphista Therapeutics

Amphista Therapeutics is focused on transforming the lives of patients with severe diseases, including cancer and neurodegenerative disease, through the advancement of next generation targeted protein degradation (TPD) medicines. Amphista is applying its proprietary warhead chemistry and mechanistic know-how to generate bifunctional targeted glues with a differentiated mechanism and leading physicochemical properties. Its portfolio offers the potential for first- and/or best-in-class assets and expanding the offering of TPD medicines beyond CRBN and VHL-based agents. Founded by Advent Life Sciences, Amphista is a spin-out of TPD expert Professor Alessio Ciulli’s laboratories at the University of Dundee. Amphista is funded by leading life science investors including Forbion, Gilde Healthcare, Novartis Venture Fund, Advent Life Sciences, Eli Lilly & Company and The Dementia Discovery Fund, and also has strategic collaborations with Bristol Myers Squibb and Merck. For more information, please visit: www.amphista.com

Amphista and the Amphista logo are all trademarks or registered trademarks of Amphista Therapeutics Limited.

 

For more information please contact:

ICR Consilium
Amber Fennell, Namrata Taak
Email: Amphista@consilium-comms.com
Tel: +44 (0)20 3709 5813

Amphista Therapeutics announces new data demonstrating in vivo efficacy and CNS activity of its mechanistically differentiated targeted protein degraders

By Amphista Therapeutics, Press Release, Private Companies
Press Release.

 

Amphista Therapeutics announces new data demonstrating in vivo efficacy and CNS activity of its mechanistically differentiated targeted protein degraders

 

  • First demonstration of efficacy in disease-relevant in vivo models for an orally delivered bifunctional non-cereblon / non-VHL-based protein degrader
  • Deep degradation of target protein is achieved in a rapid, sustained, and highly selective manner
  • Successful achievement of efficient CNS delivery for multiple degraders and demonstration of significant degradation of target protein in the brain

Cambridge, UK, January 24th, 2024 – Amphista Therapeutics (“the Company” or “Amphista”), a leader in next generation targeted protein degradation (TPD) approaches, today announces the achievement of two compelling new data sets with its next generation bifunctional degraders demonstrating in vivo efficacy and the ability to target and degrade proteins in the central nervous system (CNS).

Amphista’s degraders, which leverage a novel protein degrading mechanism, with advantages beyond first generation cereblon or VHL-based approaches, have demonstrated:

–  Sustained degradation of target protein and anti-tumor efficacy: once daily oral dosing led to statistically significant reduction in tumor burden and survival advantage in multiple in vivo disease models.

–  Rapid degradation of target protein: significant levels of degradation were induced rapidly after dosing.

Highly selective degradation of target protein: statistically significant degradation of target protein vs >8000 other proteins, including closely related homologs, when dosed at 100x DC50.

Amphista also discloses significant progress in the advancement of its technology for the treatment of neurodegenerative diseases, a key focus of the Company. These data show:

  • Amphista degraders can be rationally designed to achieve CNS penetrance with examples achieved across multiple targets.
  • Rapid degradation of target protein achieved in the brain in vivo (dog and non-human primate, and in multiple brain regions) when dosed intravenously.

Louise Modis, Chief Scientific Officer of Amphista Therapeutics, said: “We are delighted by the progress we have made in advancing our pipeline and demonstrating the potential of our unique TPD technology. To our knowledge, this is the first time an orally delivered bifunctional non-cereblon / non-VHL-based protein degrader has shown efficacy in disease-relevant in vivo models. Combined with our progress in demonstrating in vivo degradation of targets within the CNS, we are extremely excited to have achieved these key preclinical development milestones and we look forward to providing additional updates across our pipeline throughout

the year.”

Beverley Carr, Interim Chief Executive Officer of Amphista Therapeutics, said: “The last six months have been

transformative for Amphista and these new compelling in vivo data strengthen our belief that our technology has the potential to deliver differentiated protein degrader molecules with class-leading physicochemical properties, enabling us to target a wider tissue and indication scope than traditional protein degrader approaches. These data are testament to the strength of our scientific team and we are on track with our portfolio priorities, exploring the tremendous potential of our platform across multiple indications in CNS and

oncology.”

About Amphista Therapeutics

Amphista Therapeutics is focused on transforming the lives of patients with severe diseases including cancer. The company is applying its proprietary Amphista degrader platform to advance new approaches in targeted protein degradation (TPD). They aim to address the challenges faced by earlier stage TPD research and to realise the full therapeutic potential of this transformational approach. Founded by Advent Life Sciences, Amphista is a spin-out of TPD expert Professor Alessio Ciulli’s laboratories at the University of Dundee. The Company has raised over $60M to date and is funded by leading life science investors including Forbion, Gilde Healthcare, Novartis Venture Fund, Advent Life Sciences, Eli Lilly & Company and The Dementia Discovery Fund. For more information, please visit: www.amphista.com

Amphista and the Amphista logo are all trademarks of Amphista Therapeutics Limited.

For more information please contact:

Amphista Therapeutics

Beverley Carr, Interim CEO info@amphista.com

 

ICR Consilium

Amber Fennell, Namrata Taak

Email: Amphista@consilium-comms.com

Tel: +44 (0)20 3709 5813

Amphista Therapeutics Achieves First Milestone in Second Discovery Programme with Bristol Myers Squibb

By Amphista Therapeutics, Press Release, Private Companies
Press Release.

 

PRESS RELEASE

 

Amphista Therapeutics Achieves First Milestone in Second Discovery Programme with Bristol Myers Squibb

 

Cambridge, UK, September 26th, 2023 – Amphista Therapeutics (“the Company” or “Amphista”), a leader in next generation targeted protein degradation (TPD) approaches, today announces it has achieved the first milestone in the second active discovery programme under its strategic collaboration and license agreement with Bristol Myers Squibb (NYSE: BMY), triggering a payment for achieving the milestone.

This  follows the announcement of the first milestone achieved in the first discovery programme  on May 4, 2023. Both programmes are part of the original agreement with Bristol Myers Squibb, which was announced in May 4, 2022 and included a $30 million upfront payment and the potential for up to $1.25 billion in performance-based milestone payments and payment for a limited expansion of the collaboration, as well as royalties on global net sales of products.

Louise Modis, Chief Scientific Officer of Amphista Therapeutics said: “The achievement of this first milestone in the second discovery programme under Amphista’s strategic collaboration with Bristol Myers Squibb is a testament to our innovative science and ability to discover and progress at pace differentiated, novel therapeutic molecules for our pharmaceutical partners. We have now delivered milestones on both active discovery programmes in our ongoing collaboration with the company and we look forward to continuing this strong momentum. Such collaborations further validate our unique approach and ambition to overcome challenges faced by other target protein degradation modalities.  With potential for CNS penetration, we continue to expand the range of potential applications for Amphista’s therapeutic modality.”

Under the agreement, Amphista is responsible for the discovery and development of small molecule protein degraders using EclipsysTM, its next-generation TPD platform. Bristol Myers Squibb is granted a global exclusive license to the resulting degraders and will be responsible for further development and commercialization activities.

ENDS

 

About Amphista Therapeutics

Amphista Therapeutics is focused on transforming the lives of patients with severe diseases including cancer. The company is applying its proprietary Amphista degrader platform to advance new approaches in targeted protein degradation (TPD). They aim to address the challenges faced by earlier stage TPD research and to realise the full therapeutic potential of this transformational approach. Founded by Advent Life Sciences, Amphista is a spin-out of TPD expert Professor Alessio Ciulli’s laboratories at the University of Dundee. The Company has raised over $60M to date and is funded by leading life science investors including Forbion, Gilde Healthcare, Novartis Venture Fund, Advent Life Sciences, Eli Lilly & Company and The Dementia Discovery Fund. For more information, please visit: www.amphista.com  

 

For more information please contact:

Consilium Strategic Communications

Amber Fennell, Namrata Taak, Stella Lempidaki

Email: Amphista@consilium-comms.com

Tel: +44 (0)20 3709 5813

 

 

Amphista Therapeutics Achieves First Discovery Milestone in Collaboration with Bristol Myers Squibb

By Amphista Therapeutics, Press Release, Private Companies
Press Release.

 

Amphista Therapeutics Achieves First Discovery Milestone in Collaboration with Bristol Myers Squibb

4 May 2023

CAMBRIDGE, UK, May 4, 2023 – Amphista Therapeutics, a leader in next generation targeted protein degradation (TPD) approaches, today announced the delivery of the first discovery milestone under its collaboration and license agreement with Bristol Myers Squibb, triggering a payment for achieving the milestone.

Nicola Thompson, CEO of Amphista, said, “we are absolutely delighted with the progress and success of our collaboration with BMS. Our ability to deliver our first milestone within the first year of our collaboration exemplifies the strength of our Eclipsys TM platform and our ambition to be a world-leading, next generation protein degradation company.”

The collaboration and license agreement with Bristol Myers Squibb was announced on May 4, 2022 and included a $30 million upfront payment, the potential for up to $1.25 billion in performance-based milestone payments and payment for a limited expansion of the collaboration, as well as royalties on global net sales of products. Amphista is responsible for the discovery and development of small molecule protein degraders using Eclipsys TM, its next-generation TPD platform. Bristol Myers Squibb is granted a global exclusive license to the resulting degraders and will be responsible for further development and commercialization activities.

Amphista’s next generation bifunctional molecules use a novel approach that makes use of a wider range of the body’s own innate protein degrading mechanisms than those used by most other TPD companies. This proprietary approach offers the potential to overcome many of the limitations seen with current TPD approaches, providing the opportunity to treat a wider range of diseases. Amphista is focused on biological targets with a high level of clinical or genetic validation.

About Amphista Therapeutics
Amphista Therapeutics is focused on transforming the lives of patients with severe diseases including cancer. The company is applying its proprietary Amphista degrader platform to advance new approaches in targeted protein degradation (TPD). They aim to address the challenges faced by earlier stage TPD research and to realise the full therapeutic potential of this transformational approach. Founded by Advent Life Sciences, Amphista is a spin-out of TPD expert Professor Alessio Ciulli’s labs at the University of Dundee. The company has raised over $60M to date and is funded by leading life science investors including Forbion, Gilde Healthcare, Novartis Venture Fund, Advent Life Sciences, Eli Lilly & Company and The Dementia Discovery Fund.

Amphista, the Amphista logo and Eclipsys are all trademarks of Amphista Therapeutics Limited

Media contacts

Lynn Granito
Berry & Company Public Relations
lgranito@berrypr.com
+1 212 253 8881

Fierce Biotech Names Amphista Therapeutics as One of its “Fierce 15” Biotech Companies of 2022

By Amphista Therapeutics, Press Release, Private Companies
Press Release.

 

Cambridge, UK – September, 12, 2022 – Amphista Therapeutics, a leader in next generation targeted protein degradation (TPD) approaches, today announced that Fierce Biotech has named it as one of 2022’s Fierce 15 biotechnology companies, designating it as one of the most promising early-stage biotechnology companies in the industry.

Amphista is a world leading next-generation Targeted Protein Degradation (TPD) company with the mission to unlock the full therapeutic potential of TPD by addressing the limitations of first-generation approaches. Amphista advantages include: targeting of a non-cereblon component with a more consistent expression profile that enables increased tissue reach, broader disease applicability and potentially greater clinical efficacy. This mechanistic approach, leveraging an essential protein, offers the potential for reduced clinical resistance.  Amphista’s TPD therapeutics are designed to be drug-like molecules with oral bioavailability and the potential for CNS penetration.  Amphista has built a strong IP foundation for the platform including its proprietary warheads, forming the basis of a true platform approach to TPD.

Nicki Thompson, CEO of Amphista, said

“We are delighted to be selected as a ‘Fierce 15’ company in a year where we have made outstanding progress in advancing our proprietary Eclipsys™ platform and therapeutic portfolio and in expansion of our world-leading team.  This also comes in a year where our technology has been further recognized and validated by our strategic collaborations with global pharmaceutical companies Merck Healthcare, a division of Merck, and Bristol Myers Squibb worth more than $2 billion. We remain dedicated to advancing our ground-breaking science with the potential to open up this exciting modality by delivering medicines to patients across a wider range of diseases.”

Every year Fierce Biotech evaluates hundreds of early-stage companies from around the world for its annual Fierce 15 list, which is based on a variety of factors such as the strength of its technology, partnerships, venture backers and a competitive market position.  The Fierce 15 celebrates the spirit of being “fierce” – championing innovation and creativity, even in the face of intense competition.

About Fierce Biotech
Fierce Biotech is the biotech industry’s daily monitor, an email newsletter and web resource providing the latest biotech news, articles, and resources related to clinical trials, drug discovery, FDA approval, FDA regulation, patent news, pharma news, biotech company news and more. More than 450,000 top biotech professionals rely on Fierce Biotech for an insider briefing on the day’s top stories. Signup is free at www.fiercebiotech.com/signup.

About Amphista Therapeutics

Amphista Therapeutics is focused on transforming the lives of patients with severe diseases including cancer. The company is applying its proprietary Amphista degrader platform to advance new approaches in targeted protein degradation (TPD) that  address the challenges faced by earlier stage TPD research and to realise the full therapeutic potential of this transformational approach. Founded by Advent Life Sciences, Amphista is a spin-out of TPD expert Professor Alessio Ciulli’s labs at the University of Dundee. The company has raised over $60M to date and is funded by leading life science investors including Forbion, Gilde Healthcare, Novartis Venture Fund, Advent Life Sciences, BioMotiv and Eli Lilly & Company.

For more information, please visit: https://amphista.com/

CONTACTS:
Lynn Granito
Berry & Company Public Relations
lgranito@berrypr.com
212 253 8881

Amphista Therapeutics Enters Strategic Collaboration with Merck for Discovery and Development of Targeted Protein Degradation Therapeutics

By Amphista Therapeutics, Press Release, Private Companies
Press Release.

 

  • Amphista and Merck will collaborate to leverage Amphista’s proprietary EclipsysTM TPD platform and generate novel protein degrading therapeutics in oncology and immunology
  • Collaboration includes  up to €39 million ($44 million*) in combined upfront and R&D funding payments for an initial three programs
  • Amphista will potentially receive up to €893.5 million ($1.0 billion*) in total payments across three programs plus mid-single digit royalties

 

Cambridge, England, May 4th, 2022 – Amphista Therapeutics, a global leader in the discovery and development of next generation targeted protein degradation (TPD) therapeutics, today announced a strategic collaboration with Merck Healthcare, a division of Merck. Under the terms of the agreement, Merck and Amphista will work collaboratively to discover and develop small molecule protein degraders for an initial three targets in oncology and immunology indications. Amphista will receive an upfront payment, R&D funding and success-based milestone payments of up to €893.5 million ($1.0 billion*) as well as royalties in the mid-single digit range. Completion of the transaction is subject to the parties obtaining any necessary regulatory clearances or approvals.

Nicola Thompson, CEO of Amphista, said,

“We are extremely pleased to enter into this collaboration with Merck. This is a significant validation of the progress we have made in TPD research and the potential of our Eclipsys next-generation TPD platform. We look forward to working with the Merck team, using our combined expertise to develop new TPD therapies to treat cancers and immuno-inflammatory diseases.”

TPD therapies are designed to use physiological mechanisms to remove pathogenic protein from the body, offering the potential to access many disease targets previously considered “undruggable.” Amphista’s technology is specifically designed to develop next generation TPD therapeutics based on mechanistic insights and novel chemistry approaches that enable the company to develop novel protein degrading therapeutics with superior levels of efficacy and broad therapeutic applicability.

About Amphista Therapeutics

Amphista Therapeutics is a global leader in the discovery and development of next generation targeted protein degradation (TPD) medicines, addressing the challenges faced by the field to realise the full potential of this transformational modality.

The company’s proprietary EclipsysTM Platform supports development of multiple innovative therapeutic candidates able to overcome the limitations associated with traditional TPD approaches with superior levels of efficacy and broad therapeutic applicability. The Amphista team includes pioneers and established leaders in TPD research and all phases of drug discovery and development. The company is supported by leading life science investors including Forbion, Gilde Healthcare, Novartis Venture Fund, Advent Life Sciences, BioMotiv and Eli Lilly & Company.

For more information, please visit: http://www.amphista.com/.

Media Contacts:

Amphista Therapeutics
CEO Nicola Thompson
+44 (0) 7436102411
nicki@amphista.com

Berry & Company Public Relations
Doug Haslam
dhaslam@berrypr.com
+1 212 253 8881

Amphista Therapeutics Enters Strategic Collaboration with Bristol Myers Squibb for Discovery and Development of Targeted Protein Degradation Therapeutics

By Amphista Therapeutics, Press Release, Private Companies
Press Release.

 

Amphista and Bristol Myers Squibb to collaborate and leverage Amphista’s proprietary Eclipsys™ targeted protein degradation platform to develop novel protein degrading therapeutics
Collaboration includes an upfront payment of $30 million, the potential for up to $1.25 billion in performance-based milestone payments and payments for a limited expansion of the collaboration, as well as royalties on global net sales of products

 

Cambridge, England, May 4th, 2022 – Amphista Therapeutics, a global leader in the discovery and development of next generation targeted protein degradation (TPD) therapeutics, today announced a strategic collaboration and license agreement with Bristol Myers Squibb.

Under the terms of the agreement, Bristol Myers Squibb and Amphista will work collaboratively to discover and develop small molecule protein degraders.  Bristol Myers Squibb will be granted a global exclusive license to the degraders developed and will be responsible for further development and commercialization activities.  Amphista will receive a $30 million upfront payment, the potential for up to $1.25 billion in performance-based milestone payments and payment for a limited expansion of the collaboration, as well as royalties on global net sales of products. The closing of the transaction is subject to the parties obtaining regulatory clearances or approvals.

Nicola Thompson, CEO of Amphista, said,

“Our collaboration with Bristol Myers Squibb is a powerful validation of our advances in TPD research and the capabilities of our Eclipsys next-generation TPD platform.  Combining our expertise with Bristol Myers Squibb’s strong legacy and experience in the protein degradation space brings new promise to the potential of delivering more effective new treatment to patients seeking treatment options.”

TPD therapies are designed to use physiological mechanisms to remove pathogenic protein from the body, offering the potential to access many disease targets previously considered “undruggable.” Amphista’s technology is specifically designed to develop next generation TPD therapeutics based on advanced mechanistic insights and novel chemistry approaches that enable the development of novel protein degrading therapeutics.

“Bristol Myers Squibb continues to build its leadership and scientific expertise in the protein degradation space,”

said Rupert Vessey, M.A., B.M., B.Ch., FRCP, D.Phil., Executive Vice President, Research & Early Development, Bristol Myers Squibb.

“We look forward to collaborating with Amphista and using its TPD platform to potentially develop new targeted protein degradation therapies.”

 

About Amphista Therapeutics

Amphista Therapeutics is a global leader in the discovery and development of next generation targeted protein degradation (TPD) medicines, addressing the challenges faced by the field to realise the full potential of this transformational modality.

The company’s proprietary EclipsysTM Platform supports development of multiple innovative therapeutic candidates able to overcome the limitations associated with traditional TPD approaches with superior levels of efficacy and broad therapeutic applicability. The Amphista team includes pioneers and established leaders in TPD research and all phases of drug discovery and development. The company is supported by leading life science investors including Forbion, Gilde Healthcare, Novartis Venture Fund, Advent Life Sciences, BioMotiv and Eli Lilly & Company.

For more information, please visit: http://www.amphista.com/.

 

Media contacts:

Amphista Therapeutics
CEO Nicola Thompson
+44 (0) 7436102411
nicki@amphista.com

Berry & Company Public Relations
Doug Haslam
dhaslam@berrypr.com
+1 212 253 8881

Amphista Therapeutics Appoints Dr Martin Pass as CDO

By Amphista Therapeutics, Press Release, Private Companies
Press Release.

 

Amphista Therapeutics Appoints Dr Martin Pass as CDO

Cambridge, England, 6 December 2021 – Amphista Therapeutics, a leader in next generation targeted protein degradation (TPD) approaches, today announced the appointment of Dr Martin Pass, as Chief Development Officer (CDO).

Martin joins Amphista from AstraZeneca, where he was Vice President, Head Early Oncology Projects and led successful clinical development efforts. Martin has over 30 years’ experience in the pharmaceutical industry with many successes spanning early drug discovery through to Phase 3 clinical development.

Previously, Martin was a medicinal chemist at GlaxoSmithKline where he helped progress multiple candidates into clinical development in the cardiovascular, CNS and gastrointestinal therapeutic areas. He has a PhD in Organic Chemistry from Imperial College London and worked in post-doctoral research at the University of Virginia, USA. He is a co-author on over 60 patents and peer-reviewed publications.

Amphista’s CEO Dr Nicola Thompson said,

“On behalf of the Amphista team, I am delighted to welcome Martin as our CDO. Martin brings a wealth of strategic clinical development expertise from an impressive global career as a leader in clinical trials, in two world leading pharmaceutical companies. Martin’s leadership will support the realisation of the full potential of our proprietary next generation TPD technology across multiple therapy areas in order to bring transformative medicines to patients.”

Amphista’s new CDO, Dr Martin Pass, commented on his appointment,

“I’m delighted to join Amphista’s dynamic, world class team. Amphista is founded on transformational science and I am looking forward to driving the Company’s clinical development programmes and research as we pursue our mission of building the world’s leading TPD company and ultimately bringing benefit to patients.”

– Ends –

Media contacts:

Amphista Therapeutics
CEO NicolaThompson
+44 7464 974714
nicki@amphista.com

Scius Communications
Katja Stout
+44 7789 435990
katja@sciuscommunications.com

About Amphista Therapeutics
Amphista Therapeutics is focused on transforming the lives of patients with severe diseases including cancer. The company is applying its proprietary Amphista degrader platform to advance new approaches in targeted protein degradation (TPD), which address the challenges faced by the field and to realise the full therapeutic potential of this transformational approach. Founded by Advent Life Sciences, Amphista is a spin-out of TPD expert Professor Alessio Ciulli’s labs at the University of Dundee. The company has raised over $60M to date and is funded by leading life science investors including Forbion, Gilde Healthcare, Novartis Venture Fund, Advent Life Sciences, BioMotiv and Eli Lilly & Company.

For more information, please visit: http://www.amphista.com/

Amphista Therapeutics Appoints CBO, Beverley Carr

By Amphista Therapeutics, Press Release, Private Companies
Press Release.

 

Amphista Therapeutics Appoints CBO, Beverley Carr

Cambridge, England, 1 November 2021 – Amphista Therapeutics, a leader in next generation targeted protein degradation (TPD) approaches, today announced the appointment of a Chief Business Officer (CBO), Beverley Carr.

Amphista’s CEO Dr Nicola Thompson said,

“On behalf of the Amphista team, I am thrilled to welcome Beverley as our CBO.  Beverley brings a wealth of business development expertise from an impressive career as a business leader, spanning both global Pharma and Biotech. Beverley’s leadership of this strategically important function will be key to ensuring that the full potential of our proprietary next generation TPD technology is captured across therapy areas in order to bring transformative medicines to patients.”

Amphista’s new CBO, Beverley Carr, commented on her appointment,

“I’m delighted to join Amphista’s world class team. Amphista is founded on transformational science and I’m looking forward to driving the Company’s business development strategy as we execute our mission of building the leading TPD company.”

Beverley joins Amphista from Achilles Therapeutics plc (NASDAQ: ACHL), a clinical-stage biopharmaceutical company, where she was CBO. Previously Beverley was Vice President Business Development for the Immunoinflammation Therapy Area at GSK, where she led over twenty transactions for the immune-inflammation therapy area. Beverley has negotiated and closed major deals across all stages of drug discovery and development. She is a scientist by training with an MA and DPhil in chemistry from Oxford University and has an MBA from Cambridge University.

– Ends –

Media contacts:

Amphista Therapeutics
CEO NicolaThompson
+447464974714
nicki@amphista.com

Scius Communications
Katja Stout
+447789435990
katja@sciuscommunications.com

About Amphista Therapeutics

Amphista Therapeutics is focused on transforming the lives of patients with severe diseases including cancer. The company is applying its proprietary Amphista degrader platform to advance new approaches in targeted protein degradation (TPD), which address the challenges faced by the field and to realise the full therapeutic potential of this transformational approach. Founded by Advent Life Sciences, Amphista is a spin-out of TPD expert Professor Alessio Ciulli’s labs at the University of Dundee. The company has raised over $60M to date and is funded by leading life science investors including Forbion, Gilde Healthcare, Novartis Venture Fund, Advent Life Sciences, BioMotiv and Eli Lilly & Company.
For more information, please visit: http://www.amphista.com/